Related Experiment Video
Updated: Aug 16, 2026
The Use of Reverse Phase Protein Arrays (RPPA) to Explore Protein Expression Variation within Individual Renal Cell Cancers
Published on: January 22, 2013
Carbonic anhydrase IX and the future of molecular markers in renal cell carcinoma
John T Leppert1, John S Lam, Allan J Pantuck
1Department of Urology, David Geffen School of Medicine at UCLA, Los Angeles, CA, USA.
Abstract:
The use of carbonic anhydrase IX as a promising molecular marker in RCC is described by authors from Los Angeles, who discuss the promise that molecular markers hold to improve diagnosis, staging, treatment, surveillance and survival of patients with RCC. There is a whole range of new treatments being introduced in the management of metastatic renal cancer. The use of VEGF-targeted therapy has particular importance, especially as it has a strong genetically linked rationale for its potential success in this area. Authors from the USA show that substantial clinical activity has been reported in initial clinical trials. In prostate cancer, drugs targeting microtubules, such as taxanes, have already been introduced clinically, and their success has received widespread attention. A new group of drugs, the epothilones, have similar but not identical binding properties to microtubules, and authors from the USA describe how they have shown activity in hormone-refractory prostate cancer, and are moving to phase III testing.
Insights
Carbonic anhydrase IX shows promise as a molecular marker for renal cell carcinoma (RCC), potentially improving patient diagnosis and treatment. New therapies, including VEGF-targeted treatments and epothilones for prostate cancer, are advancing clinical management.
Area of Science:
- Oncology
- Molecular Biology
- Pharmacology
Background:
- Renal cell carcinoma (RCC) management is evolving with new therapeutic strategies.
- Molecular markers hold significant promise for improving RCC patient outcomes.
- Advances in targeted therapies are crucial for treating metastatic cancers.
Purpose of the Study:
- To highlight the potential of carbonic anhydrase IX as a molecular marker in RCC.
- To discuss the role of novel molecular markers in enhancing RCC diagnosis, staging, treatment, surveillance, and survival.
- To review emerging treatments for metastatic renal cancer and prostate cancer.
Main Methods:
- Review of current literature on molecular markers in RCC.
- Discussion of VEGF-targeted therapies and their clinical activity.
- Analysis of microtubule-targeting agents, including taxanes and epothilones, in prostate cancer.
Main Results:
- Carbonic anhydrase IX is identified as a promising molecular marker for RCC.
- VEGF-targeted therapy demonstrates substantial clinical activity in initial trials for metastatic renal cancer.
- Epothilones show activity in hormone-refractory prostate cancer and are progressing to phase III testing.
Conclusions:
- Molecular markers like carbonic anhydrase IX can significantly improve RCC patient care.
- Targeted therapies, including VEGF inhibitors, represent a key advancement in treating renal and prostate cancers.
- Further research and clinical trials are essential for validating new therapeutic approaches in oncology.